Outcome | Age (years) | Total in each group | % positive | OR 95% CI | Wald test P value |
---|---|---|---|---|---|
Infection by PCR ( baseline survey )* | 0-4 | 788 [27.5] | Â | 1 | <0.001 |
 | 5-9 | 622 [47.9] |  | 2.80 [2.17-3.62] | <0.001 |
 | 10-15 | 413 [50.1] |  | 3.26 [2.44-4.35] | 0.005 |
 | 16-25 | 409 [33.7] |  | 1.52 [1.13-2.04] | 0.721 |
 | 26-35 | 328 [26.5] |  | 0.94 [0.68-1.30] | 0.007 |
 | 36+ | 496 [20.6] |  | 0.66 [0.49-0.89] |  |
Infection by PCR ( follow - up survey ) | 0-4 | 824 [42.4] | Â | 1 | <0.001 |
 | 5-9 | 644 [68.8] |  | 4.77 [3.52-6.47] | <0.001 |
 | 10-15 | 359 [70.2] |  | 5.58 [3.84-8.10] | <0.001 |
 | 16-25 | 445 [52.8] |  | 1.96 [1.41-2.73] | 0.661 |
 | 26-35 | 337 [44.8] |  | 1.08 [0.75-1.56] | 0.393 |
 | 36+ | 637 [39.7] |  | 0.87 [0.63-1.20] |  |
AMA -1 seropositivity (baseline survey ) | 0-4 | 688 [21.7] | Â | 1 | <0.001 |
 | 5-9 | 517 [53.0] |  | 5.13 [3.84-6.86] | <0.001 |
 | 10-15 | 321 [64.2] |  | 8.87 [6.29-12.50] | <0.001 |
 | 16-25 | 354 [60.2] |  | 7.60 [5.47-10.56] | <0.001 |
 | 26-35 | 294 [51.0] |  | 4.60 [3.29-6.42] | <0.001 |
 | 36+ | 416 [50.5] |  | 4.39 [3.24-5.96] |  |
MSP-1 19 seropositivity (baseline survey) | 0-4 | 698 [14.5] | Â | 1 | 0.111 |
 | 5-9 | 568 [16.9] |  | 1.31 [0.94-1.84] | <0.001 |
 | 10-15 | 346 [30.6] |  | 3.21 [2.24-4.59] | <0.001 |
 | 16-25 | 361 [34.9] |  | 3.90 [2.75-5.51] | <0.001 |
 | 26-35 | 291 [38.5] |  | 4.90 [3.39-7.07] | <0.001 |
 | 36+ | 447 [40.3] |  | 5.10 [3.66-7.10] |  |